Skip to content
About
Management
Board of Directors
Scientific Advisory Board
Therapeutic Areas
Pipeline
OLX07010 in Rare Tauopathies
OLX07010 Alzheimer’s
Technology
MOA
Patents
News & Publications
Partners and Collaborators
Contact Us
Menu
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Home
>
News
>
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Print
Oligomerix
>
News
>
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Post navigation
Previous Post
Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases
Next Post
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
vera
View posts by vera
Scroll to top
close ×
